Sadowski, D. C., Camilleri, M., Chey, W. D., Leontiadis, G. I., Marshall, J. K., Shaffer, E. A., ... & Walters, J. R. (2020). Canadian Association of Gastroenterology clinical practice guideline on the management of bile acid diarrhea. Journal of the Canadian Association of Gastroenterology, 3(1), e10-e27. doi.org/10.1093/jcag/gwz038 Vítek, L. (2015). Bile acid malabsorption in inflammatory bowel disease. Inflammatory bowel diseases, 21(2), 476-483. doi.org/10.1097/MIB.0000000000000193

Dubinsky, M. C., Dotan, I., Rubin, D. T., Bernauer, M., Patel, D., Cheung, R., ... & Keefer, L. (2021). Burden of comorbid anxiety and depression in patients with inflammatory bowel disease: a systematic literature review. Expert review of gastroenterology & hepatology, 15(9), 985-997. doi.org/10.1080/17474124.2021.1911644 Graff, L. A., Fowler, S., Jones, J. L., Benchimol, E. I., Bitton, A., Huang, J. G., ... & Bernstein, C. N. (2021). Crohn’s and Colitis Canada’s 2021 Impact of COVID-19 and Inflammatory Bowel Disease in Canada: Mental Health and Quality of Life. Journal of the Canadian Association of Gastroenterology, 4(Supplement_2), S46-S53. doi.org/10.1093/jcag/gwab031 Qazi, T. (2020). Fatigue in inflammatory bowel disease: A problematic ailment. Current Opinion in Gastroenterology, 36(4), 284-294. doi.org/10.1097/mog.0000000000000644 (Subscription may be required)

Click, B. & Regueiro, M. Managing risks with biologics. Current Gastroenterology Reports 21.1 (2019): 1-11. doi.org/10.1007/s11894-019-0669-6 (Subscription may be required) Quezada, S. M., McLean, L. P., & Cross, R. K. (2018). Adverse events in IBD therapy: the 2018 update. Expert Review of Gastroenterology & Hepatology, 12(12), 1183-1191. doi.org/10.1080/17474124.2018.1545574 (Subscription may be required)

Nistor, O. I., Godfrey, C., Ross-White, A., & Wilson, R. (2022). Systematic Review and Meta-analysis on the Incidence, Prevalence and Determinants of Discomfort in Inflammatory Bowel Disease. Journal of the Canadian Association of Gastroenterology, 5(2), 96-97. doi.org/10.1093/jcag/gwab043

Chauhan, U., Stitt, L., Rohatinsky, N., Watson, M., Currie, B., Westin, L., ... & Nistor, I. (2022). Patients’ Access to Telephone and E-mail Services Provided by IBD Nurses in Canada. Journal of the Canadian Association of Gastroenterology, 5(3), 129-136. https://doi.org/10.1093/jcag/gwab041

Bernstein, C. N., Benchimol, E. I., Bitton, A., Murthy, S. K., Nguyen, G. C., Lee, K., ... & Kaplan, G. G. (2019). The impact of inflammatory bowel disease in Canada 2018: Extra-intestinal diseases in IBD. Journal of the Canadian Association of Gastroenterology, 2(Supplement_1), S73-S80. doi.org/10.1093/jcag/gwy053 Garber, A., & Regueiro, M. (2019). Extraintestinal manifestations of inflammatory bowel disease: epidemiology, etiopathogenesis, and management. Current gastroenterology reports, 21(7), 1-13. doi.org/10.1007/s11894-019-0698-1 Yokoda, R. T., & Carey, E. J. (2019). Primary biliary cholangitis and primary sclerosing cholangitis. Official journal of the American College of Gastroenterology| ACG, 114(10), 1593-1605. doi.org/10.14309/ajg.0000000000000268 (Subpscription may be required)

Roda, G., Chien Ng, S., Kotze, P. G., Argollo, M., Panaccione, R., Spinelli, A., ... & Danese, S. (2020). Crohn’s disease. Nature Reviews Disease Primers, 6(1), 1-19. https://doi.org/10.1038/s41572-020-0156-2 (Subscription required) Mayo Clinic (2019) Ulcerative Colitis. (PDF) Gajendran, M., Loganathan, P., Catinella, A. P., & Hashash, J. G. (2018). A comprehensive review and update on Crohn's disease. Disease-a-month, 64(2), 20-57. https://doi.org/10.1016/j.disamonth.2017.07.001 Gallo, G., Kotze, P. G., & Spinelli, A. (2018). Surgery in ulcerative colitis: When? How? Best practice & research. Clinical gastroenterology, 32, 71-78. https://doi.org/10.1016/j.bpg.2018.05.017 (Subscription required)

Gonczi, L., Bessissow, T., & Lakatos, P. L. (2019). Disease monitoring strategies in inflammatory bowel diseases: What do we mean by “tight control”?. World journal of gastroenterology, 25(41), 6172. doi.org/10.3748/wjg.v25.i41.6172 Rodrigues, B. L., Mazzaro, M. C., Nagasako, C. K., Ayrizono, M. D. L. S., Fagundes, J. J., & Leal, R. F. (2020). Assessment of disease activity in inflammatory bowel diseases: Non-invasive biomarkers and endoscopic scores. World Journal of Gastrointestinal Endoscopy, 12(12), 504. doi.org/10.4253/wjge.v12.i12.504 Walsh, A. J., Bryant, R. V., & Travis, S. P. (2016). Current best practice for disease activity assessment in IBD. Nature reviews Gastroenterology & hepatology, 13(10), 567-579. doi.org/10.1038/nrgastro.2016.128 (Subscription may be required)

Ghishan, F. K., & Kiela, P. R. (2017). Vitamins and minerals in inflammatory bowel disease. Gastroenterology Clinics, 46(4), 797-808. doi.org/10.1007/s11938-019-00248-z (Subscription may be required) Green, N., Miller, T., Suskind, D., & Lee, D. (2019). A review of dietary therapy for IBD and a vision for the future. Nutrients, 11(5), 947. doi.org/10.3390/nu11050947 Gu, P., & Feagins, L. A. (2020). Dining with inflammatory bowel disease: a review of the literature on diet in the pathogenesis and management of IBD. Inflammatory Bowel Diseases, 26(2), 181-191. doi.org/10.1093/ibd/izz268 Li, S., Ney, M., Eslamparast, T., Vandermeer, B., Ismond, K. P., Kroeker, K., ... & Tandon, P. (2019). Systematic review of nutrition screening and assessment in inflammatory bowel disease. World journal of gastroenterology, 25(28), 3823. doi.org/10.3748/wjg.v25.i28.3823 Mentella, M. C., Scaldaferri, F., Pizzoferrato, M., Gasbarrini, A., & Miggiano, G. A. D. (2020). Nutrition, IBD and gut microbiota: a review. Nutrients, 12(4), 944. doi.org/10.3390/nu12040944 Picardo, S., Altuwaijri, M., Devlin, S. M., & Seow, C. H. (2020). Complementary and alternative medications in the management of inflammatory bowel disease. Therapeutic Advances in Gastroenterology, 13, 1756284820927550. doi.org/10.1177/1756284820927550 Weber, A. T., Shah, N. D., Sauk, J., & Limketkai, B. N. (2019). Popular diet trends for inflammatory bowel diseases: claims and evidence. Current Treatment Options in Gastroenterology, 17(4), 564-576. doi.org/10.1007/s11938-019-00248-z (Subscription may be required)

Leddin, D., Lieberman, D. A., Tse, F., Barkun, A. N., Abou-Setta, A. M., Marshall, J. K., ... & Leontiadis, G. I. (2018). Clinical practice guideline on screening for colorectal cancer in individuals with a family history of nonhereditary colorectal cancer or adenoma: the Canadian Association of Gastroenterology Banff Consensus. Gastroenterology, 155(5), 1325-1347. doi.org/10.1053/j.gastro.2018.08.017 Farraye, F. A., Melmed, G. Y., Lichtenstein, G. R., & Kane, S. V. (2017). ACG clinical guideline: preventive care in inflammatory bowel disease. Official journal of the American College of Gastroenterology| ACG, 112(2), 241-258. doi.org/10.1038/ajg.2016.537 Abegunde, A. T., Muhammad, B. H., & Ali, T. (2016). Preventive health measures in inflammatory bowel disease. World journal of gastroenterology, 22(34), 7625. doi.org/10.3748/wjg.v22.i34.7625

Review on current and novel treatment for IBD Abbass, M., Cepek, J., Parker, C. E., Nguyen, T. M., MacDonald, J. K., Feagan, B. G., ... & Jairath, V. (2019). Adalimumab for induction of remission in Crohn's disease. Cochrane Database of Systematic Reviews, (11). doi.org/10.1002/14651858.CD012878.pub2 Na, S. Y., & Moon, W. (2019). Perspectives on current and novel treatments for inflammatory bowel disease. Gut and Liver, 13(6), 604. doi.org/10.5009/gnl19019 Challenges in maintaining long-term remission Ashton, J. J., Green, Z., Kolimarala, V., & Beattie, R. M. (2019). Inflammatory bowel disease: Long-term therapeutic challenges. Expert Review of Gastroenterology & Hepatology, 13(11), 1049-1063. doi.org/10.1080/17474124.2019.1685872 (Subscription may be required) Review of strategies to treat to target Colombel, J. F., D’haens, G., Lee, W. J., Petersson, J., & Panaccione, R. (2020). Outcomes and strategies to support a treat-to-target approach in inflammatory bowel disease: a systematic review. Journal of Crohn's and Colitis, 14(2), 254-266. doi.org/10.1093/ecco-jcc/jjz131 Anemia and iron therapy in IBD Kumar, A., & Brookes, M. J. (2020). Iron therapy in inflammatory bowel disease. Nutrients, 12(11), 3478. doi.org/10.3390/nu12113478 Patel, D., Trivedi, C., & Khan, N. (2018). Management of anemia in patients with inflammatory bowel disease (IBD). Current treatment options in gastroenterology, 16(1), 112-128. doi.org/10.1007/s11938-018-0174-2 (Subscription may be required) Strategies to manage perianal disease Nguyen, G. C. (2018). The Bottom Line: A Multidisciplinary Approach Is Key to Treating Perianal Fistulizing Crohn’s Disease. Journal of the Canadian Association of Gastroenterology, 1(4), 139. doi.org/10.1093/ecco-jcc/jjz131 Treat to target strategies and review on STRIDE-II Turner, D., Ricciuto, A., Lewis, A., D’amico, F., Dhaliwal, J., Griffiths, A. M., ... & Dignass, A. (2021). STRIDE-II: An update on the Selecting Therapeutic Targets in Inflammatory Bowel Disease (STRIDE) initiative of the International Organization for the Study of IBD (IOIBD): determining therapeutic goals for treat-to-target strategies in IBD. Gastroenterology, 160(5), 1570-1583. doi.org/10.1053/j.gastro.2020.12.031 Practical guide for thiopurine monitoring in IBD. Warner, B., Johnston, E., Arenas-Hernandez, M., Marinaki, A., Irving, P., & Sanderson, J. (2018). A practical guide to thiopurine prescribing and monitoring in IBD. Frontline Gastroenterology, 9(1), 10-15. doi.org/10.1136/flgastro-2016-100738

Ananthakrishnan, A. N., Martin, C., Kane, S., Sandler, R. S., & Long, M. D. (2019). Paternal disease activity is associated with difficulty in conception among men with inflammatory bowel diseases. Clinical Gastroenterology and Hepatology, 17(1), 203-204. doi.org/10.1016/j.cgh.2018.04.001 Leenhardt, R., Rivière, P., Papazian, P., Nion-Larmurier, I., Girard, G., Laharie, D., & Marteau, P. (2019). Sexual health and fertility for individuals with inflammatory bowel disease. World Journal of Gastroenterology, 25(36), 5423. doi.org/10.3748/wjg.v25.i36.5423 ​ Management of IBD during pregnancy Nguyen, G. C., Seow, C. H., Maxwell, C., Huang, V., Leung, Y., Jones, J., ... & Paterson, W. (2016). The Toronto consensus statements for the management of inflammatory bowel disease in pregnancy. Gastroenterology, 150(3), 734-757. doi.org/10.1053/j.gastro.2015.12.003

Singh, S., Picardo, S., & Seow, C. H. (2020). Management of inflammatory bowel diseases in special populations: obese, old, or obstetric. Clinical Gastroenterology and Hepatology, 18(6), 1367-1380. https://doi.org/10.1016/j.cgh.2019.11.009 (Subscription may be required)

Canadian IBD Nursing (CANIBD) is a community of practice for nurses that are working in the field of IBD who help to ensure people of all ages living with IBD in Canada receive high-quality clinical nursing care within a multidisciplinary team. CANIBD has developed several resources for IBD nurses and healthcare providers, such as biologic therapy teaching tools for ulcerative colitis and Crohn's disease, as well as vaccination guidelines. Access these resources and more here. Learn more about CANIBD.

The Canadian Associaton of Gastroenterology (CAG) offers a number of resources to support high quality digestive health clinical care for Canadians, such as: CAG Quality Improvement Programs - An overview of several CAG programs, including improving endoscopic skills, evaluating endoscopic service as well as physician practice comparison to national results for self-evaluative purposes. Canada-Global Rating Scale (C-GRS) - The C-GRS examines 12 items related to Clinical Quality and the Quality of the Patient Experience. Inflammatory Bowel Disease- Global Rating Scale (IBD-GRS) - The Global Rating Scale (GRS) is a web-based self-assessment quality improvement tool used to identify gaps in health care, change the focus to patient-centred care and standardize care.

For provider information about virtual health care, please visit your province's webpage: Alberta Health Services - Virtual Health Saskatchewan Health Authority - Virtual Care Manitoba - MBTelehealth Ontario Health - Ontario Telemedicine Network Réseau québécois de la télésanté Nova Scotia Health - Virtual Care Habashi, P., Bouchard, B. & Nguyen, G.C., On Behalf of the Promoting Access and Care through Centres of Excellence (PACE) Network. (2019) Transforming Access to Specialist Care for Inflammatory Bowel Disease: The PACE Telemedicine Program, Journal of the Canadian Association of Gastroenterology, Volume 2, Issue 4, Dec 2019, 186–194, doi.org/10.1093/jcag/gwy046

Clinical Practice Guidelines Managing luminal Crohn’s Disease Panaccione, R., Steinhart, A. H., Bressler, B., Khanna, R., Marshall, J. K., Targownik, L., ... & Bernstein, C. N. (2019). Canadian Association of Gastroenterology clinical practice guideline for the management of luminal Crohn’s disease. Journal of the Canadian Association of Gastroenterology, 2(3), e1-e34. https://doi.org/10.1093/jcag/gwz019 Management of Perianal Crohn’s Disease (2019) Steinhart, A. H., Panaccione, R., Targownik, L., Bressler, B., Khanna, R., Marshall, J. K., ... & Williams, C. (2019). Clinical practice guideline for the medical management of perianal fistulizing Crohn’s disease: the Toronto consensus. Inflammatory bowel diseases, 25(1), 1-13. https://doi.org/10.1093/ibd/izy247 Management of nonhospitalized UC (2015) Bressler, B., Marshall, J. K., Bernstein, C. N., Bitton, A., Jones, J., Leontiadis, G. I., ... & Williams, C. (2015). Clinical practice guidelines for the medical management of nonhospitalized ulcerative colitis: the Toronto consensus. Gastroenterology, 148(5), 1035-1058. https://doi.org/10.1053/j.gastro.2015.03.001 Management of IBS Moayyedi, P., Andrews, C. N., MacQueen, G., Korownyk, C., Marsiglio, M., Graff, L., ... & Vanner, S. (2019). Canadian Association of Gastroenterology clinical practice guideline for the management of irritable bowel syndrome (IBS). Journal of the Canadian Association of Gastroenterology, 2(1), 6-29. https://doi.org/10.1093/jcag/gwy071 Management of bile acid diarrhea Sadowski, D. C., Camilleri, M., Chey, W. D., Leontiadis, G. I., Marshall, J. K., Shaffer, E. A., ... & Walters, J. R. (2020). Canadian Association of Gastroenterology clinical practice guideline on the management of bile acid diarrhea. Journal of the Canadian Association of Gastroenterology, 3(1), e10-e27. https://doi.org/10.1093/jcag/gwz038 Vaccinations for IBD patients Benchimol, E. I., Tse, F., Carroll, M. W., deBruyn, J. C., McNeil, S. A., Pham-Huy, A., ... & Jones, J. L. (2021). Canadian Association of Gastroenterology clinical practice guideline for immunizations in patients with inflammatory bowel disease (IBD)—part 1: Live vaccines. Journal of the Canadian Association of Gastroenterology, 4(4), e59-e71. https://doi.org/10.1093/jcag/gwab015 Jones, J. L., Tse, F., Carroll, M. W., deBruyn, J. C., McNeil, S. A., Pham-Huy, A., ... & Benchimol, E. I. (2021). Canadian Association of Gastroenterology clinical practice guideline for immunizations in patients with inflammatory bowel disease (IBD)—Part 2: Inactivated vaccines. Journal of the Canadian Association of Gastroenterology, 4(4), e72-e91. https://doi.org/10.1093/jcag/gwab016 Papp, K. A., Haraoui, B., Kumar, D., Marshall, J. K., Bissonnette, R., Bitton, A., ... & Wade, J. (2019). Vaccination guidelines for patients with immune-mediated disorders on immunosuppressive therapies—executive summary. Journal of the Canadian Association of Gastroenterology, 2(4), 149-152. https://doi.org/10.1093/jcag/gwy069 Consensus Statements Transition of IBD patients from pediatric to adult care Fu, N., Bollegala, N., Jacobson, K., Kroeker, K. I., Frost, K., Afif, W., ... & Benchimol, E. I. (2022). Canadian consensus statements on the transition of adolescents and young adults with Inflammatory Bowel Disease from pediatric to adult care: A collaborative initiative between the Canadian IBD Transition Network and Crohn’s and Colitis Canada. Journal of the Canadian Association of Gastroenterology, 5(3), 105-115. https://doi.org/10.1093/jcag/gwab050 Management of IBD during pregnancy Nguyen, G. C., Seow, C. H., Maxwell, C., Huang, V., Leung, Y., Jones, J., ... & Paterson, W. (2016). The Toronto consensus statements for the management of inflammatory bowel disease in pregnancy. Gastroenterology, 150(3), 734-757. https://doi.org/10.1053/j.gastro.2015.12.003 European nursing roles in IBD (N-ECCO) Kemp, K., Dibley, L., Chauhan, U., Greveson, K., Jäghult, S., Ashton, K., ... & Bager, P. (2018). Second N-ECCO consensus statements on the European nursing roles in caring for patients with Crohn’s disease or ulcerative colitis. Journal of Crohn's and Colitis, 12(7), 760-776. https://doi.org/10.1093/ecco-jcc/jjy020

Clinical care pathways (CCP) are structured, standardized, evidence-based multidisciplinary management algorithms, identifying an appropriate sequence of clinical interventions and timeframes for IBD patients. Sixteen (16) IBD CCPs were developed by IBD Unit Specialists at the University of Alberta and University of Calgary. IBD CCPs are supported by systematic reviews of published evidence and are comprised of protocols, algorithms and checklists that help to harmonize clinical and administrative aspects and ensure continuity of IBD care in outpatient settings. All IBD CCPs can be found at ibdclinic.ca/tools-for-hcps, including the IBD flare pathway for optimal management of an IBD flare and corticosteroid pathway for the initiation and maintenance of corticosteroids to minimize the risk of repeated corticosteroids.

Nursing Textbooks Readers can use these books to enhance understanding of all apsects of IBD, including diagnostics, treatment and other aspects of IBD IBD Nursing (2010). Edited by Marion O’Connor. NACSCORP, INC; 1st edition ​IBD Nursing Manual (2019). Edited by Andreas Sturm and Lydia White. Springer Cham, 1at Edition. https://link.springer.com/book/10.1007/978-3-319-75022-4 Abdominal Examinations Physical exam skills (videos) Practical guide to clinical medicine - Exam of the abdomen Crohn's and Colitis Canada also provides several resources to support patients with IBD. Visit the Information & Resource Hub.

How will patients be referred to the program? Patients would be identified from within the current patient roster at the IBD clinic in Saskatoon. There is no formal multidisciplinary IBD program in Regina yet, but Dr. Bhasin is working on establishing this. For now, patients from Regina would likely be identified from Dr. Bhasin's practice. Who will refer patients to the program? Currently patients are referred to the IBD centre in Saskatoon (or to Dr. Bhasin in Regina who is GI with IBD training) from general practitioners (GPs), General Surgery, and from GI who do not focus on IBD. New patients who are referred in to the IBD center would be flagged if they are in remote locations as these patients would benefit most from the virtual care program. What is the process for referring patients to virtual care? (Current processes, if any exist?) For the past 2 years, the majority of patients have been seen virtually. If on initial virtual assessment they are found to require an in person visit, this is then arranged (visit for physical exam, visit for scope or IUS, etc). Clients must be referred by a Gastroenterologist affiliated with the Multidisciplinary IBD Clinic at the Royal University Hospital. Schedule: Clients will be followed through clinic appointments or by individual appointments depending on the needs of the individual patient. Inflammatory Bowel Disease Referral form

How will patients be referred to the program? Virtual Hallway (VH) is a platform that embeds evidence-based referral algorithms. In instances when a physician or NP from a rural or underserviced region is referring to Nova Scotia Collaborative IBD Program (NSCIBD) Centre of Excellence (COE), these referrals will come in via VH through a smart referral algorithm that will incorporate clinical decision support at the time a referral for an IBD flare is made. The intent of this platform is to improve the quality of the referral and to improve efficiency and appropriateness of the referral process. Who will refer patients to the program? A physician or NP from a rural or underserviced region will refer patients. In Nova Scotia, given lack of resourcing for dedicated virtual care nurses, as well as underservicing in primary care, the proposed model will engage community-based internists and general gastroenterologists, offering them and their patients the support services of the Virtual IBD Nurse Navigation (VINN) to empower and incentivize local IBD care delivery. What is the process for referring patients to virtual care? (Current processes, if any exist?) To be determined.

The Ontario IBD virtual care program is dedicated to serving patients living with Crohn’s disease and Ulcerative Colitis who reside in underserviced locations throughout Ontario. Referrals are accepted for adult patients living at least 100 kms from Mount Sinai Hospital in Toronto. How to be referred to the Ontario IBD virtual care program The PACE IBD telemedicine program accepts referrals from physicians and nurse practitioners for the following reasons: to assist with the diagnosis of IBD, to assume ongoing IBD management, or for a second opinion regarding treatment and care of IBD Along with the completed referral form, the referring health care provider should include: recent medical imaging results endoscopy and surgical reports relevant lab work The referral form and supporting documents should be faxed to the IBD Telemedicine: 416-586-5971 or emailed to PaceIBD.MSH@SinaiHealth.ca PACE IBD Referral Form For further information, please contact: Peter Habashi, RN Mount Sinai Hospital Zane Cohen Centre for Digestive Diseases Phone: 416-586-4800 x 2188 Fax: 416-586-5971 Em: Peter.habashi@SinaiHealth.ca

CaNVAS-IBD Quebec Program is dedicated to serving patients living with Crohn's disease and ulcerative colitis who reside in underserviced locations throughout Quebec. We accept referrals for adult patients living at least 100 kms from the Montreal General Hospital. Patients in the CaNVAS-IBD Quebec program have access to real-time medical consultations from Gastroenterologists who specialize in IBD management. Telemedicine essentially involves a health care specialist speaking to a patient through videoconferencing technology similar to Skype or FaceTime, but with a secured computer network. Through the use of this technology, our program endeavors to minimize the disruption, stress and cost that can be associated with travel to Montreal for IBD related medical appointments. We will use Teams for Healthcare in our virtual care program. How will patients be referred to the program? The referral process will be as follows: (1) Patients already being seen at the McGill University Health Centre (MUHC) IBD clinic but live remotely, (2) Lead gastroenterologist (GI) triages all IBD referral to the clinic and will identify eligible referrals, (3) Corridor of service with Hull/Gatineau already established and will offer virtual care service (4) GIs routinely travel to Northern QC area for colonoscopies and will identify eligible IBD patients. Who will refer patients to the program? The CaNVAS-IBD Quebec program accepts referrals from physicians and nurse practitioners for the following reasons: 1. to assist with the diagnosis of IBD, 2. to assume ongoing IBD management, or 3. for a second opinion regarding treatment and care of IBD Along with the completed referral form, the referring health care provider should include: - recent medical imaging results - endoscopy and surgical reports - relevant lab work What is the process for referring patients to virtual care? The referral form and supporting documents can be emailed to: jennifer.laneuville@muhc.mcgill.ca or faxed at 514-843-2891 Once your referral has been triaged by one of our IBD specialists, you will be contacted by the IBD Telemedicine nurse from the Montreal General Hospital with the date and time of your telemedicine appointment. Le programme RCaVAS-MII Québec est destiné aux patients atteints de la maladie de Crohn et de la colite ulcéreuse qui habitent dans des régions mal desservies du Québec. Nous acceptons les patients adultes qui habitent à au moins 100 km de l’Hôpital général de Montréal. Les patients du programme RCaVAS-MII Québec ont accès à des consultations médicales en temps réel de la part de gastro-entérologues spécialisés dans la prise en charge des MII. La télémédecine implique essentiellement qu’un spécialiste des soins de santé parle à un patient par le bias d’une technologie de vidéoconférence similaire à Skype ou FaceTime, mais avec un réseau informatique sécurisé. Grâce à cette technologie, notre programme s’efforce de minimiser les perturbations, le stress et les coûts qui peuvent être associés aux déplacements à Montréal pour les rendez-vous médicaux liés aux MII. Nous utiliserons Teams pour Healthcare dans notre programme de soins virtuels. Comment les patients seront-ils orientés vers le programme ? Le processus de référence est le suivant : (1) Les patients déjà vus à la clinique des MII du Centre universitaire de santé McGill (CSUM) mais vivant à distance, (2) Le gastro-entérologue en chef trie tous les cas de MII adressés à la clinique et identifiera les cas admissibles, (3) Un corridor de service avec Hull/Gatineau est déjà établi et offrira un service de soins virtuels (4) Les gastro-entérologues se rendent régulièrement dans le nord du Québec pour des coloscopies et identifieront les patients atteints de MII admissibles. Qui oriente les patients vers le programme ? Le programme RCaVAS-MII Québec accepte les recommandations des médecins et des infirmières praticiennes pour les raisons suivantes : 1. Pour aider au diagnostic des MII, 2. Pour prendre en charge la gestion continue des MII, ou 3. Pour obtenir un deuxième avis sur le traitement et la prise en charge des MII Le fournisseur de soins de santé qui adresse le patient doit joindre au formulaire d’orientation rempli les documents suivants : - les résultats d’imagerie médicale récents - les rapports d’endoscopie et de chirurgie - les résultats de laboratoire pertinents Quel est le processus pour référer des patients aux soins virtuels ? Le formulaire de recommandation et les documents à l’appui peuvent être envoyés par courriel à jennifer.laneuville@muhc.mcgill.ca ou par télécopieur au 514-843-2891. Une fois que votre recommandation aura été triée par l’un de nos spécialistes des MII, l’infirmière de télémédecine des MII de l’Hôpital général de Montréal communiquera avec vous pour vous indiquer la date et l’heure de votre rendez-vous par télémédecine.

How will patients be referred to the program? Patient requirements; only bona fide diagnosis of IBD (not for people who are worried they have IBD). Patients or physicians with IBD patients can call the clinic directly. Who will refer patients to the program? Patients can be self-referred or a physician or nurse practitioner caring for a patient with IBD can call in for advice or to refer the patient. What is the process for referring patients to virtual care? (Current processes, if any exist?) The nurse practitioner will have a phone visit with the patient and/or health care provider. The program’s gastroenterologists can then elect to have a virtual care visit with the patient either by phone or by video or if needed an in-person visit.

How will patients be referred to the program? Stay tuned for more details to come. Who will refer patients to the program? Stay tuned for more details to come. What is the process for referring patients to virtual care? (Current processes, if any exist?) Stay tuned for more details to come. .

Visit Quebec Telehealth (weblink) to learn more about this program, including its advantages. Visit Telehealth Resources for patients and family members. It also provides information on how to participate in a virtual meeting and elements to consider for a virtual appointment.

Visit Ontario Telemedicine Network (OTN) (weblink) for more information about virtual care in Ontario. The OTN eVisit handout (PDF) provides an overview of an eVisit appointment, including what is needed to do an eVisit, how it works, and privacy reassurances.

https://myhealth.alberta.ca/Health/Pages/conditions.aspx?hwid=acl2140&lang=en-ca Provides an overview of virtual care and how it works. Shares examples of when virtual care is a good option and what are some of the risks.

Visit Virtual Care Nova Scotia (weblink) for more information about the program, including registration and a detailed breakdown of what to expect during a virtual appointment.

https://mbtelehealth.ca/about/faqs/ A resource that explains MBTelehealth, some of the reasons to use it as well as what to expect when booking and attending a telehealth appointment. https://northernhealthregion.com/programs-and-services/mb-telehealth/ An overview of MBTelehealth including confidentiality and what happens on the day of an appointment. A list of Telehealth locations is provided. https://sharedhealthmb.ca/files/covid-19-virtual-care-toolkit.pdf A step-by-step checklist of how to prepare for a “Virtual Care Encounter” (appointment online, by phone or email).

https://www.saskhealthauthority.ca/your-health/conditions-diseases-services/healthline-online/acl2140 Provides an overview of virtual care and how it works. Shares examples of when virtual care is a good option and what are some of the risks. https://www.ehealthsask.ca/residents/pages/telehealth.aspx An overview of Telehealth in Saskatchewan including some of the areas of service that commonly use telehealth. Shares examples of the benefits of Telehealth as well as statistics relating to the use of Telehealth in Saskatchewan.

Under construction